Lamivudine Tablets

  • Medicine name- Lamivir
  • API- Lamivudine
  • Pack Size- strip of 10 tablets
  • Strength- 150 mg and 300 mg
  • Marketed by: Cipla Ltd
Get an Enquiry


Lamivudine tablet is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Limitations of Use: The dosage of this product is for HIV-1 and not for HBV.

Dosage and Side Effects

  • Adults: 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily. 

  • Pediatric Patients Aged 3 Months and Older: Administered either once or twice daily. Dose should be calculated on body weight (kg) and should not exceed 300 mg daily. 

  • Patients with Renal Impairment: Doses of Lamivudine must be adjusted in accordance with renal function.

The most common reported adverse reactions (incidence greater than or equal to 15%) in adults were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough. 

The most common reported adverse reactions (incidence greater than or equal to 15%) in pediatric subjects were fever and cough.

Warning and Precautions

  • Co-infected HIV-1/HBV Patients: Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. 

  • Hepatic decompensation, some fatal, has occurred in HIV-1/HCV co-infected patients receiving interferon and ribavirin-based regimens. Monitor for treatment-associated toxicities. Discontinue Lamivudine as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both.

  • Pancreatitis: Use with caution in pediatric patients with a history of pancreatitis or other significant risk factors for pancreatitis. Discontinue treatment as clinically appropriate.

  • Immune reconstitution syndrome and redistribution/accumulation of body fat have been reported in patients treated with combination antiretroviral therapy.

  • Lower virologic suppression rates and increased risk of viral resistance were observed in pediatric subjects who received Lamivudine oral solution concomitantly with other antiretroviral oral solutions compared with those who received tablets. An all-tablet regimen should be used when possible.